Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces...
News
Alterity Therapeutics to Present at MST Financial Webinar
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
BOSTON and SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in at-home sleep monitoring and computational...
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
Over 100,000 individuals lost their lives from overdoses last year, the majority of which were opioid related. While opioid overdoses...
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollmentFOSTER CITY, Calif., July 24, 2024 (GLOBE...
Compass Pathways to announce second quarter financial results on August 1, 2024
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access...
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Tilray's Solução Oral THC10:CBD10 Medical Cannabis Extract is Now Approved for Medical Use in PortugalCANTANHEDE, Portugal, July 24, 2024 (GLOBE...
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following...
Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate)...
Tiziana Life Sciences Granted FDA Fast Track Designation
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Asensus Surgical Announces The Rocky Mountain Hospital for Children in Denver, Colorado to Initiate Senhance Surgery Program
First Senhance® System placement at a dedicated pediatric hospital in the United StatesRESEARCH TRIANGLE PARK, N.C., July 24, 2024 (GLOBE...
Teleflex Announces the Teleflex Center for Antimicrobial Protection
WAYNE, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today...
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apneaSAN DIEGO, July...
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to...
Malaysia Healthcare Travel Council Launches Experience Malaysia Healthcare (EMH) Stories
From Womb to Tomb: A Story of an OB-GYN | Faces of Malaysia Healthcare EP 1 Life in Every Drop:...
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab...
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the...
Policymakers should recognise #SelfCareIsHealthcare in campaign bid to address global health challenges
Self-care is healthcare Self-care is healthcare Self-care describes the role of individuals in preventing disease, promoting and maintaining their mental...
STERIS to Host a Conference Call for Fiscal 2025 First Quarter Financial Results on August 7, 2024
DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it...